Topline Results Phase 3 MANIFEST-2 Study Pelabresib in First-Line Myelofibrosis November 2023 Gail, Living with Myelofibrosis since 2018

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL"), the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "would", "could", "potential", "possible", "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and tafasitamab/Minjuvi® in relapsed or refractory DLBCL). The safety and efficacy of these investigational products have not been established and there is no guarantee any investigational product will be approved by regulatory authorities. Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Forward-Looking Statements 2© MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study

3 Agenda 01 Opening Remarks Jean-Paul Kress, M.D., Chief Executive Officer (CEO) 02 Phase 3 MANIFEST-2 Study Topline Results Tim Demuth, M.D., Ph.D., Chief Research & Development Officer (CR&DO) 03 Myelofibrosis in Clinical Practice John Mascarenhas, M.D., Professor of Medicine and Director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, New York 04 Q&A Jean-Paul Kress, M.D., Tim Demuth, M.D., Ph.D., Lucinda Crabtree, Ph.D., John Mascarenhas, M.D. © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study

MANIFEST-2 Study Results Demonstrate Most Impressive Benefits Seen in Clinical Studies of Patients with Myelofibrosis © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study 4 Pelabresib is an investigational medicine that has not yet been approved by any regulatory authorities. KEY FINDINGS • Achieved primary endpoint, nearly doubling SVR35 • Significant improvements in key secondary endpoints (absolute change in TSS and TSS50) for intermediate-risk patients • Strong positive trend in key secondary endpoints for overall population • Clinically meaningful anemia improvement • Safety results consistent with prior trials, no new safety signals NEXT STEPS Present detailed findings at 2023 ASH Annual Meeting Submit for approval in the U.S. and Europe mid-2024

Phase 3 MANIFEST-2 Study: One of the Largest Myelofibrosis Studies Ever Conducted 5 KEY ENDPOINTS SECONDARY: Absolute change in TSS at week 24 TSS50 at week 24 (MFSAF v4.0) PRIMARY: SVR35 at week 24 ADDITIONAL ENDPOINTS* Improvement in bone marrow fibrosis Progression-free survival Overall survival Duration of the splenic response JAK-inhibitor-naïve myelofibrosis patients randomized, representative of the disease population and aligned with NCCN criteria 430 Hemoglobin response Duration of the symptom response © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study SVR35, ≥35% reduction in spleen volume; TSS, total symptom score; TSS50, ≥50% reduction in total symptom score; MFSAF, Myelof ibrosis Symptom Assessment Form *Only includes sample of additional endpoints being assessed in Phase 3 MANIFEST-2 study

Statistically Significant and Clinically Meaningful Improvement in Primary Endpoint: SVR35 © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study 6 *Difference calculated using Cochran–Mantel–Haenszel (CMH) common risk difference POPULATION SVR35 (Pelabresib + Ruxolitinib) SVR35 (Ruxolitinib + Placebo) Difference All Patients (N = 430) 66% 35% 30.4%* P-value: p<0.001 Intermediate-Risk (DIPSS Int-1 & 2) (N = 400) 66% 36% 29.9%* P-value: p<0.001 High-Risk (DIPSS) (N = 30) 64% 25% 39.3% P-value: 0.063

*Least square mean estimate; **No calculation due to missing data rate; ***Difference calculated using Cochran–Mantel–Haenszel (CMH) common risk difference POPULATION Absolute Change in TSS (Pelabresib + Ruxolitinib) Absolute Change in TSS (Ruxolitinib + Placebo) Difference TSS50 (Pelabresib + Ruxolitinib) TSS50 (Ruxolitinib + Placebo) Difference All Patients (N = 430) -15.99 -14.05 -1.94* P-value: 0.0545 52% 46% 6.0%*** P-value: 0.216 Intermediate- Risk (DIPSS Int-1 & 2) (N = 400) -15.18 -12.74 -2.4* P-value: <0.02 55% 45% 10.05%*** P-value: <0.05 High-Risk (DIPSS) (N = 30) N/A** N/A** N/A** 21% 69% -47.3% P-value: <0.05 Strong Positive Trend in Key Secondary Endpoints: Absolute Change in TSS and TSS50 © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study 7

Myelofibrosis in Clinical Practice JOHN MASCARENHAS, M.D. Professor of Medicine and Director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, New York © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study

9 Passamonti, F et al. Hematological Oncology 2021; Szuber N, et al. Mayo Clinic 2019; Passamonti, F et al. Blood 2010 Enlarged Spleen Anemia Bone Marrow Fibrosis 4 2 1 3 Constitutional Symptoms MEDIAN OVERALL SURVIVAL (DIPSS) + Intermediate-risk: ~4 – 14.2 years + High-risk: ~1.5 years DIAGNOSIS (DIPSS) + Intermediate-risk: ~77% – 86% + High-risk: ~9% – 11% Myelofibrosis is a Debilitating, Progressive and Often Deadly Blood Cancer, Characterized by Four Hallmarks © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study

Survival Improves With Spleen Length Reduction in Patients Receiving Ruxolitinib MONTHS For <25% vs ≥50% spleen length reduction: HR: 0.22 (95% CI: 0.10–0.51; P = .0001)P R O B A B IL IT Y O F O S 0 0 366 12 18 24 30 4842 0.2 0.4 0.6 0.8 1.0 ≥50% spleen length reduction (n = 61) ≥25% but <50% spleen length reduction (n = 13) <25% spleen length reduction (n = 23) 10© MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study OPEN-LABEL, SINGLE-ARM PHASE I/II STUDY (N = 107) HR, hazard ratio; OS, overall survival. | Verstovsek S, et al. Blood. 2012;120:1202-1209.

11 The RR6 model was validated in another cohort of patients (n = 40; P = 0.0276) treated with ruxolitinib at Moffitt Cancer Center RR6 = response to ruxolitinib after 6 months | Maffioli M. Blood Adv. 2022;6 (6):1855-1864. Risk Factors Multivariate, HR (95% CI); P-value RUX dose below 20 mg BID at baseline, 3 months and 6 months HR = 1.79 (1.07-3.00); P = 0.03 Splenomegaly reduction ≤30% by palpation at 3 months and 6 months HR = 2.26 (1.40-3.65); P = 0.0009 RBC transfusion need at baseline, 3 months and 6 months HR = 2.32 (1.19-4.54); P = 0.02 © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study RR6: Three Factors Predict Survival Benefit

© MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study 12 MANIFEST-2 Provides Valuable Evidence, Cementing Position of Pelabresib and Ruxolitinib Combination Potential 1. BET inhibition is rational and supported by pre-clinical data 2. Combination of pelabresib and ruxolitinib is clinically active • SVR35 statistically significant and clinically meaningful in overall population • Strong numerical improvement in symptom reduction, significant improvement in intermediate-risk patients 3. Well-tolerated therapy • Safety results consistent with prior trials, no new safety signals 4. Correlative evidence of biologic disease modification • Hemoglobin level improvement • Anemia AE improvement 5. Paradigm Shift – Combination Therapy: • Support use of combination treatment • Start early to prevent patients getting more ill

Most Impressive Benefits Seen in Myelofibrosis File for Approval in the U.S. and Ex-U.S. Multi-Billion Dollar Market Opportunity Pelabresib and Ruxolitinib Combination Therapy: Potential to Shift Treatment Paradigm in Myelofibrosis © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study 13

Q&A Tim Demuth, M.D., Ph.D. Jean-Paul Kress, M.D. © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study Lucinda Crabtree, Ph.D. John Mascarenhas, M.D.

Thank you! www.MorphoSys.com © MorphoSys – Topline Results: Phase 3 MANIFEST-2 Study